2015 BIO International Convention in Philadelphia
PHILADELPHIA, PA, USA
June 15-18, 2015
Advaxis and Sorrento Form Collaboration to Evaluate Combinations of Advaxis’s Lm-LLO Immunotherapy Technology and Sorrento’s Immunomodulatory Antibodies
PRINCETON, N.J. and SAN DIEGO, May 19, 2015 – Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive research and clinical trial collaboration agreement with Sorrento Therapeutics, Inc. (Nasdaq:SRNE) to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform, including ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento’s fully human antibodies targeting immune checkpoints, including GITR, OX40, LAG-3 and TIM-3. Sorrento has one of the largest and most diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody (mAb) product candidates.
Cortendo AB: Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
GOTEBORG, SWEDEN and TREVOSE, PA, USA and VICTORIA, AUSTRALIA, May 15, 2015 – Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for endocrinology applications. Destum Partners acted as Antisense Therapeutics’ exclusive transaction advisor throughout the process.